Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Leases (2019 - 2025)

Historic Current Leases for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $11.9 million.

  • Kymera Therapeutics' Current Leases rose 299.79% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year increase of 299.79%. This contributed to the annual value of $11.6 million for FY2024, which is 12876.87% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Current Leases of $11.9 million as of Q3 2025, which was up 299.79% from $11.8 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Current Leases peaked at $11.9 million during Q3 2025, and registered a low of $2.4 million during Q1 2021.
  • Moreover, its 5-year median value for Current Leases was $2.6 million (2023), whereas its average is $5.8 million.
  • Per our database at Business Quant, Kymera Therapeutics' Current Leases crashed by 1061.11% in 2021 and then soared by 34520.65% in 2024.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Current Leases stood at $2.5 million in 2021, then rose by 3.01% to $2.5 million in 2022, then soared by 99.92% to $5.1 million in 2023, then soared by 128.77% to $11.6 million in 2024, then grew by 2.23% to $11.9 million in 2025.
  • Its last three reported values are $11.9 million in Q3 2025, $11.8 million for Q2 2025, and $11.7 million during Q1 2025.